Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Moleculin Biotech, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +2 vs. Q4 2024
- Shares held
- 1.48M
- +1.01M (+218.1%) vs. Q4 2024
- Total value
- $1.44M
- +$648.9K (+82.1%) vs. Q4 2024
- New holders
- 6
- 5 more added
- Sold out
- 4
- 3 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MBRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $518.5K |
| Q1 2026 | 20 | $347.9K |
| Q4 2025 | 17 | $315.2K |
| Q3 2025 | 25 | $412.7K |
| Q2 2025 | 22 | $117.9K |
| Q1 2025 | 23 | $1.44M |
| Q4 2024 | 21 | $790.0K |
| Q3 2024 | 19 | $1.31M |
| Q2 2024 | 16 | $1.10M |
| Q1 2024 | 19 | $1.53M |
| Q4 2023 | 24 | $4.44M |
| Q3 2023 | 22 | $925.1K |
| Q2 2023 | 22 | $1.33M |
| Q1 2023 | 23 | $2.91M |
| Q4 2022 | 25 | $3.17M |
| Q3 2022 | 27 | $3.16M |
| Q2 2022 | 26 | $4.32M |
| Q1 2022 | 23 | $5.26M |
| Q4 2021 | 26 | $5.61M |
| Q3 2021 | 24 | $8.57M |
| Q2 2021 | 32 | $10.9M |
| Q1 2021 | 29 | $8.74M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Moleculin Biotech, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 1 | $0 | 0.00% | 00.0% | Unchanged |
| North Star Investment Management Corp. | 17 | $17 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 32 | $31 | 0.00% | −72−69.2% | Reduced |
| CVA Family Office, LLC | 34 | $33 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 34 | $33 | 0.00% | +34 | New |
| Advisor Group Holdings, Inc. | 43 | $41 | 0.00% | −6−12.2% | Reduced |
| Sandy Spring Bank | 89 | $87 | 0.00% | 00.0% | Unchanged |
| Bogart Wealth, LLC | 300 | $292 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 344 | $335 | 0.00% | +344 | New |
| SBI Securities Co., Ltd. | 746 | $726 | 0.00% | +341+84.2% | Added |
| Morgan Stanley | 926 | $901 | 0.00% | +500+117.4% | Added |
| Tower Research Capital LLC (TRC) | 1,348 | $1.31K | 0.00% | −2,676−66.5% | Reduced |
| Newbridge Financial Services Group, Inc. | 1,367 | $1.33K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 2,788 | $2.71K | 0.00% | +2,788 | New |
| Truist Financial Corp | 10,500 | $10.2K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 11,575 | $11.3K | 0.00% | +11,575 | New |
| Cambridge Investment Research Advisors, Inc. | 12,781 | $12.0K | 0.00% | +12,781 | New |
| BlackRock, Inc. | 12,380 | $12.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 26,057 | $25.4K | 0.00% | +4,033+18.3% | Added |
| Vanguard Group Inc | 30,935 | $30.1K | 0.00% | 00.0% | Unchanged |
| LPL Financial LLC | 46,080 | $44.9K | 0.00% | +4,865+11.8% | Added |
| Cetera Investment Advisers | 70,000 | $68.2K | 0.00% | +70,000 | New |
| Armistice Capital, LLC | 1,250,000 | $1.22M | 0.03% | +932,414+293.6% | Added |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −11,496−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −8,939−100.0% | Sold out |
| Atticus Wealth Management, LLC | 0 | $0 | 0.00% | −2,784−100.0% | Sold out |
| Kestra Investment Management, LLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |